Focus Of Tariff Conversations Shifts To Stability, AdvaMed Says

 
• By Elizabeth Orr
  
Trade group AdvaMed is focusing on ensuring stable, predictable medtech tariffs in 2026. (photobyphotoboy/Shutterstock)

More from US FDA

More from Medtech Insight